chlorpheniramine maleate, ibuprofen, and phenylephrine hydrochloride
ADVIL ALLERGY AND CONGESTION RELIEF (chlorpheniramine maleate, ibuprofen, and phenylephrine hydrochloride) by GSK is cyclooxygenase inhibitors [moa]. First approved in 2011.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
ADVIL Allergy and Congestion Relief is an oral tablet combining ibuprofen (NSAID), chlorpheniramine maleate (antihistamine), and phenylephrine hydrochloride (decongestant) to treat multi-symptom cold and allergy relief. It works by inhibiting cyclooxygenase to reduce inflammation and pain while addressing congestion and allergic symptoms. This fixed-dose combination targets consumers seeking convenience in treating multiple concurrent symptoms.
Product is at peak lifecycle stage in the mature OTC cough-cold category; team size likely stable with focus on maintaining market share against generic and private-label alternatives.
Cyclooxygenase Inhibitors
Nonsteroidal Anti-inflammatory Drug
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on ADVIL Allergy and Congestion Relief offers career experience in mature OTC brand management, retail channel strategy, and competitive positioning in a commoditized category. Opportunities exist in brand defense, promotional strategy, and consumer engagement but growth potential is limited by market saturation and declining pricing power.
Worked on ADVIL ALLERGY AND CONGESTION RELIEF at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.